• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Editas Medicine, Inc. - Common Stock (NQ:EDIT)

    2.365 +0.255 (+12.09%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 3, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Editas Medicine, Inc. - Common Stock

    < Previous 1 2
    ...
    6 7 8 9 10 11 12 13 Next >
    News headline image
    Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy ↗
    -Clinical Data Due Next Week at ASH- 
    Via Benzinga
    Analyst Ratings for Editas Medicine ↗
     
    Via Benzinga
    News headline image
    2 Beaten-Down Stocks to Watch Closely Next Year ↗
    These biotechs could skyrocket in 2023, but only if they can execute their plans. 
    Via The Motley Fool
    News headline image
    Editas Medicine Touts Positive Safety, Efficacy Data From Two Sickle Cell Disease Patients ↗
     
    Via Benzinga
    News headline image
    Why Shares of Editas Medicine Dropped 15.5% in November ↗
    The biotech's shares plummeted after it paused a key clinical trial. 
    Via The Motley Fool
    News headline image
    Why Editas Medicine's Shares Are Falling Thursday ↗
    The company shelved a clinical trial for one of its lead therapies. 
    Via The Motley Fool
    News headline image
    Editas Medicine: Q3 Earnings Insights ↗
    Editas Medicine (NASDAQ:EDIT) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    News headline image
    Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Where Will Editas Medicine Be in 1 Year? ↗
    The company could continue lagging the market for a while. 
    Via The Motley Fool
    News headline image
    Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment ↗
     
    Via Benzinga
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022 ↗
    Upgrades 
    Via Benzinga
    News headline image
    Palo Alto To Surge Around 38%? Plus This Analyst Predicts $65 For Helmerich & Payne ↗
    Barclays raised the price target on Palo Alto Networks, Inc. (NASDAQ: PANW) from $200 to $215. Barclays analyst Saket Kalia maintained an Overweight rating on the stock. Palo Alto Networks shares fell... 
    Via Benzinga
    News headline image
    Intuit To $490? Here Are 5 Other Price Target Changes For Friday ↗
    Barclays cut Intuit Inc. (NASDAQ: INTU) price target from $502 to $490. . Barclays analyst Raimo Lenschow maintained an Overweight rating on the stock. Intuit shares fell 3% to close at $381.88 on... 
    Via Benzinga
    News headline image
    Gap To Rally 18%? Plus This Analyst Slashes PT On Super League Gaming By 50% ↗
      Telsey Advisory Group boosted the price target on The Gap, Inc. (NYSE: GPS) from $10 to $15. Gap shares rose 5.6% to close at $12.71 on Thursday. 
    Via Benzinga
    News headline image
    Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday ↗
    Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday. 
    Via Benzinga
    News headline image
    Nasdaq Down 60 Points; Alibaba Posts Upbeat Q2 Earnings ↗
    U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 60 points on Thursday. 
    Via Benzinga
    News headline image
    Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday's Mid-Day Session ↗
    Gainers Elevate Credit, Inc. (NYSE: ELVT) shares surged 71.2% to $1.8150 after the company agreed to be acquired by Park Cities Asset Management in an all-cash transaction at an implied value of $67... 
    Via Benzinga
    News headline image
    Citing Small Population, Editas Medicine Pauses Work On Gene Therapy Trial For Genetic Eye Disorder ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    S&P 500 Down 1%; Crude Oil Drops Sharply ↗
    U.S. stocks traded lower midway through trading, with the S&P 500 dropping around 1% on Thursday. 
    Via Benzinga
    News headline image
    BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday ↗
    U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session. 
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    What 5 Analyst Ratings Have To Say About Editas Medicine ↗
    Over the past 3 months, 5 analysts have published their opinion on Editas Medicine (NASDAQ:EDIT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
    Via Benzinga
    News headline image
    Editas Medicine Announces Third Quarter 2022 Results and Business Updates
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022 ↗
    Upgrades 
    Via Benzinga
    < Previous 1 2
    ...
    6 7 8 9 10 11 12 13 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.